CureVac NV

( )
CVAC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -2.01%167.240.7%$966.93m
ABBVAbbVie, Inc. 0.81%142.081.9%$836.18m
PFEPfizer Inc. -3.26%48.320.9%$816.98m
LLYEli Lilly & Co. -1.03%301.461.1%$775.81m
MRKMerck & Co., Inc. -0.30%88.920.7%$771.89m
BMYBristol-Myers Squibb Co. -0.52%74.471.0%$667.79m
SIGASIGA Technologies, Inc. 8.25%24.790.0%$465.44m
AZNAstraZeneca Plc -1.80%64.651.0%$355.61m
ALNYAlnylam Pharmaceuticals, Inc. -1.13%229.398.2%$281.63m
GBTGlobal Blood Therapeutics, Inc. -0.40%66.575.6%$275.23m
GSKGSK Plc -6.67%35.750.3%$212.12m
HZNPHorizon Therapeutics Plc -1.92%67.105.4%$208.58m
NVONovo Nordisk A/S 1.20%108.800.1%$177.13m
NVSNovartis AG -2.23%85.480.2%$175.53m
CCXIChemoCentryx, Inc. -0.53%50.602.9%$174.75m

Company Profile

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.